You have completed learning Topic 4: Acceptability. Remember these key points:

• Only 3.2% of NuvaRing^® experienced nausea, and only 2.6% experienced breast tenderness.
• The low dosage and steady release of homones may contribute to low incidences adverse reactions.
• There is no greater incidence of vaginitis in women who use NuvaRing^® as compared to the general population.
• Ninety-seven percent of NuvaRing^® users would recommend NuvaRing^® to someone else.

Click HERE to return to the Topic Menu, or click Next to begin Topic 5.